Cargando…

A Successful Coronary Artery Bypass Operation with Intermittent Factor VIII Administration in a Hemophilia A Patient Who Was Admitted Due to Acute Myocardial Infarction: A Rare and Difficult Case

Detalles Bibliográficos
Autores principales:	Topaloğlu, Ulaş Serkan, Özmen, Rıfat, Yüksel, Recep Civan, Çetin, Murat, Akyol, Gülşah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516099/ https://www.ncbi.nlm.nih.gov/pubmed/30468434 http://dx.doi.org/10.4274/tjh.galenos.2018.2018.0271

Ejemplares similares

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors
por: Veeranki, Sreenivas P, et al.
Publicado: (2021)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Pulmonary Embolism in Acquired Hemophilia A: A Rare Complication With Factor VIII Inhibitor Bypassing Activity Therapy
por: Aslam, Hafiz M, et al.
Publicado: (2020)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Comparison of “burden of disease” in elderly and non-elderly patients with pre-diabetes: A cross-sectional study
por: Topaloglu, Ulas Serkan, et al.
Publicado: (2020)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
por: Han, Jeong Pil, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
por: Roth, Stefanie D., et al.
Publicado: (2012)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII
por: Chen, Hainan, et al.
Publicado: (2019)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019)

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
por: Abrantes, João A., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice
por: Song, Shuxian, et al.
Publicado: (2022)

Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A
por: Gong, Jie, et al.
Publicado: (2021)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
por: Yoo, Ki Young, et al.
Publicado: (2016)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9apf959m15mr8btlemlqvodruk